For-Cause Audit

A for-cause audit is a compliance review opened because of a specific triggering event — a monitoring finding, a complaint, a safety signal, or evidence of a possible deviation — rather than as part of a pre-planned, periodic audit schedule. The trigger is what separates a for-cause audit from every other audit category in clinical research quality assurance.

For-cause vs. routine, directed, and scheduled audits

Clinical research quality assurance functions (and FDA’s own Bioresearch Monitoring program) generally recognize a small set of audit/inspection categories, distinguished by what prompts them:

• Routine (surveillance) audit — conducted on a periodic basis for ongoing regulated activity (an active site, an active IRB, a laboratory), independent of any known problem.
• Directed audit — focused on specific activities or data tied to a particular submission or marketing application, without necessarily implying a compliance concern.
• For-cause audit — opened specifically because of a complaint, required report, safety signal, or identified deviation. May be unannounced, and is typically narrower in scope but more intensive than a routine audit, focused on the specific concern that triggered it.

These same three categories appear in FDA’s own Bioresearch Monitoring compliance programs, which govern for-cause inspections of clinical investigators, sponsors, monitors, CROs, and IRBs — see the FDA BIMO (Bioresearch Monitoring) Program term for the full inspection taxonomy and scope. A sponsor’s internal quality assurance function typically mirrors this same routine/directed/for-cause structure for its own site and vendor audits, independent of whether FDA is involved.

Two contexts: FDA for-cause inspections and sponsor-initiated for-cause audits

The term shows up in two related but distinct settings:

FDA for-cause BIMO inspection. FDA’s field-inspection function opens a for-cause inspection of an investigator, sponsor, monitor, CRO, or IRB in response to a specific complaint, a required safety report, or a data-integrity signal — for example, following an allegation of fabricated case report form data submitted in support of a marketing application. These inspections may be unannounced and are scoped to the specific concern rather than a comprehensive review of the entire site or program.

Sponsor- or CRO-initiated for-cause audit. A sponsor’s or CRO’s clinical quality assurance group opens a for-cause audit of a trial site, investigator, or vendor when a monitoring visit, a safety report, or another oversight mechanism surfaces a specific red flag — for instance, a monitor’s visit report documenting repeated missing source documentation for adverse events, or discrepancies between the Delegation of Authority (DoA) Log and who is actually performing trial tasks at the site. This is a purely internal, contractual quality-assurance mechanism — it does not require FDA involvement, though findings from a sponsor for-cause audit can prompt (or, less commonly, follow) an FDA for-cause inspection of the same site.

Common triggers

• A monitoring visit report identifying a serious or recurring protocol deviation
• An unexpected pattern or rate of serious adverse events at a site
• A complaint from a subject, staff member, or whistleblower
• Evidence suggesting possible data fabrication, falsification, or other data integrity concerns
• A required regulatory report (e.g., an IND safety report) that raises compliance questions
• Findings from a prior routine audit that warrant deeper, targeted follow-up

What follows a for-cause audit

A for-cause audit that substantiates the underlying concern typically produces formal audit findings requiring a documented remediation plan. See Audit Corrective Action Plan (Grants) for the closely related grants-management analog, and CAPA (Corrective and Preventive Action) for the broader corrective/preventive action framework a clinical research site or sponsor uses to close out audit findings and prevent recurrence.

Frequently Asked Questions

What triggers a for-cause audit?

A for-cause audit opens in response to a specific triggering event rather than on a routine schedule. Common triggers include a monitoring visit report flagging a serious or recurring protocol deviation, an unexpected pattern of serious adverse events, a complaint from a subject or staff member, evidence of possible data fabrication or falsification, a required regulatory report that raises compliance questions, or findings from a prior routine audit that warrant deeper, targeted follow-up.

How is a for-cause audit different from a routine audit?

A routine (surveillance) audit is conducted periodically for ongoing regulated activity, independent of any known problem. A for-cause audit, by contrast, is opened specifically because of a complaint, required report, safety signal, or identified deviation, and is typically narrower in scope but more intensive than a routine audit, focused on the specific concern that triggered it.

Who conducts a for-cause audit at a clinical trial site?

A sponsor’s or CRO’s clinical quality assurance group typically opens a for-cause audit of a trial site, investigator, or vendor when a monitoring visit, safety report, or other oversight mechanism surfaces a specific red flag — for example, repeated missing source documentation for adverse events, or discrepancies between the Delegation of Authority (DoA) Log and who is actually performing trial tasks at the site.

Is a for-cause audit the same as an FDA for-cause inspection?

They are related but not identical. An FDA for-cause BIMO inspection is opened by FDA’s own field-inspection function in response to a complaint, required safety report, or data-integrity signal. A sponsor- or CRO-initiated for-cause audit is a separate, purely internal contractual quality-assurance mechanism that does not require FDA involvement, though findings from one can prompt — or, less commonly, follow — the other at the same site.

Can a for-cause audit be unannounced?

Yes. Because a for-cause audit responds to a specific triggering event rather than a pre-planned schedule, it may be unannounced. This applies to FDA for-cause BIMO inspections as well as sponsor- or CRO-initiated audits.

What happens after a for-cause audit finds a compliance issue?

A for-cause audit that substantiates the underlying concern typically produces formal audit findings that require a documented remediation plan. In clinical research this remediation is generally managed through a CAPA (Corrective and Preventive Action) process; the grants-management equivalent is an Audit Corrective Action Plan.